Evidence map›Paper›PMID 27129256›Full record

ArticleThe Journal of biological chemistry2016

Silencing of Small Valosin-containing Protein-interacting Protein (SVIP) Reduces Very Low Density Lipoprotein (VLDL) Secretion from Rat Hepatocytes by Disrupting Its Endoplasmic Reticulum (ER)-to-Golgi Trafficking.

Samata Tiwari, Shaila Siddiqi, Olga Zhelyabovska, Shadab A Siddiqi

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. SVIP alleviates CClCell death & disease · 2019
    Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Samata TiwariBurnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida 32827.
Shaila SiddiqiBurnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida 32827.
Olga ZhelyabovskaBurnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida 32827.
Shadab A SiddiqiBurnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida 32827. Electronic address: shadab.siddiqi@ucf.edu.
University of Central Florida · US

Funding

A Cell Biological Approach to Hepatic Lipid MetabolismR01DK081413 · NIDDK · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI SIDDIQI, SHADAB A · 2008 to 2017
$2.7M
NIDDK NIH HHS R01 DK081413
6 · The paper itself

Abstract

The transport of nascent very low density lipoprotein (VLDL) particles from the endoplasmic reticulum (ER) to the Golgi determines their secretion by the liver and is mediated by a specialized ER-derived vesicle, the VLDL transport vesicle (VTV). Our previous studies have shown that the formation of ER-derived VTV requires proteins in addition to coat complex II proteins. The VTV proteome revealed that a 9-kDa protein, small valosin-containing protein-interacting protein (SVIP), is uniquely present in these specialized vesicles. Our biochemical and morphological data indicate that the VTV contains SVIP. Using confocal microscopy and co-immunoprecipitation assays, we show that SVIP co-localizes with apolipoprotein B-100 (apoB100) and specifically interacts with VLDL apoB100 and coat complex II proteins. Treatment of ER membranes with myristic acid in the presence of cytosol increases SVIP recruitment to the ER in a concentration-dependent manner. Furthermore, we show that myristic acid treatment of hepatocytes increases both VTV budding and VLDL secretion. To determine the role of SVIP in VTV formation, we either blocked the SVIP protein using specific antibodies or silenced SVIP by siRNA in hepatocytes. Our results show that both blocking and silencing of SVIP lead to significant reduction in VTV formation. Additionally, we show that silencing of SVIP reduces VLDL secretion, suggesting a physiological role of SVIP in intracellular VLDL trafficking and secretion. We conclude that SVIP acts as a novel regulator of VTV formation by interacting with its cargo and coat proteins and has significant implications in VLDL secretion by hepatocytes.

Indexed as

AnimalsApolipoprotein B-100Cells, CulturedEndoplasmic ReticulumGolgi ApparatusHepatocytesImmunoblottingLipoproteins, VLDLMaleMicroscopy, ConfocalMyristic AcidNuclear ProteinsProtein BindingProtein TransportRats, Sprague-DawleyRNA InterferenceApolipoprotein B-100Lipoproteins, VLDLMyristic AcidNuclear ProteinsSVIP protein, ratTriglyceridesVesicular Transport ProteinsCOPIIendoplasmic reticulum (ER)lipoprotein secretionsmall VCP-interacting protein (SVIP)triglyceridevalosin-containing protein (VCP)very low density lipoprotein (VLDL)vesiclesVLDL transport vesicle (VTV)

Identifiers

PMID27129256
PMCPMC4933472
OpenAlexW2414447301

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.